Mictamid® is a non-resorbable, injectable, transparent, hydrophilic gel, for soft tissue bulking.
Mictamid® consists of a backbone of cross-linked polyacrylamide, with water molecules loosely bound to the polymer matrix. Nominal proportions of the Mictamid® gel are 2.5% cross-linked polyacrylamide and 97.5% non-pyrogenic water for injection. Mictamid® is biocompatible and non-biodegradable and is sterilized by moist heat.
Mictamid® is supplied in a pre-filled, sterile, 1 mL syringe sealed with a Luer lock fitting. It is intended to be injected with a sterile 20-23G hypodermic needle.
Mictamid® is for soft tissue use only and must be administered by a qualified veterinarian familiar with the procedure in the intended species. Animals may be sedated to minimize stress and discomfort. Strict aseptic conditions must be followed at all times.
The Veterinary Surgeons Act doesn’t permit the ‘injection’ into any body cavity by anyone other than a vet.
Volume required depends on urethral size and conformation.
Coaptation ranges between 3-10 mls of Mictamid®.
Polyacrylamide hydrogel products, although often considered equal, have clear differences in composition and manufacturing quality, as well as their ability to interact with surrounding tissues. These characteristics, together with the injection technique used, determine the safety and effectiveness of each product.
Mictamid® is injected into the submucosa of the urethra. Upon injection into the submucosa, Mictamid® incorporates into the surrounding tissue. It provides additional volume to the urethra in the form of a cushion-like, three-dimensional stable scaffold for cells to grow through.
Mictamid® is intended to improve urethral coaptation.
Vesicovaginal reflux: A pool of urine collects cranially in the vagina, sometimes partially covering the cervix and flowing into the uterus, particularly when the cervix is relaxed during estrus. The pooling of urine in the anterior of the vagina is a fairly common cause of infertility in mares.
Aetiologies of the condition: related to poor body condition, conformational defects, weight loss, age-related change, or following perineal trauma during parturition or service or mares that have received an unsuccessful urethral extension or similar corrective surgery.
Cases suitable for treatment with Mictamid® are mares that pool urine constantly or intermittently.
Urinary issues caused by neurologic disorders have not been evaluated.
Following the procedure broad-spectrum antibiotics may be administered to decrease the risk of infection.
Non-steroidal anti-inflammatory medications are recommended for 2-3 days post-procedure.
The mare should be monitored until first normal urination. Mare can return to normal activity immediately.
As with all transcutaneous procedures, a Mictamid® injection carries a risk of infection. Standard precautions such as skin preparation and sterile technique associated with the implantable material should be followed. In the event of infection, the use of broad-spectrum antibiotics is recommended as a first-line treatment. Use of any corticosteroids is contraindicated in case of infection.
Overcorrection using Mictamid® may lead to obstruction. The product can be removed by needle aspiration or puncturing and squeezing. This can also be done in case of a low-grade chronic infection.
There is a risk of mild hematoma. If this reaction is not caused by infection, it is self-limiting and will resolve within 1 week.
The owner of the animal should be informed about the indications, expected results, contraindications, precautions, warnings and potential complications. The owner of the animal should be advised that in case of complications the veterinarian, who performed the Mictamid® injections should be contacted immediately for necessary treatment.
Mictamid® must be stored below 25°C (air conditioning) protected from direct sunlight. Do not freeze. Do not store unsealed syringes for later use.
Please click on the link below to download the Mictamid® Information For Use document.